Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NALBUPHINE HYDROCHLORIDE vs ALTOPREV
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mixed agonist-antagonist at mu-opioid receptor; full agonist at kappa-opioid receptor; weak antagonist at mu-opioid receptor.
Competitive inhibitor of HMG-Co A reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to upregulation of LDL receptors and increased clearance of LDL cholesterol.
Moderate to severe pain,Supplement to balanced anesthesia,Preoperative and postoperative analgesia,Obstetrical analgesia during labor and delivery
Heterozygous familial hypercholesterolemia,Polygenic hypercholesterolemia,Mixed dyslipidemia,Prevention of cardiovascular events (FDA-approved),Primary prevention of coronary heart disease
10-20 mg IM/IV/SC every 3-6 hours as needed; maximum single dose 20 mg, maximum daily dose 160 mg.
Lovastatin extended-release: Initial 20, 40, or 60 mg orally once daily at bedtime; titrate every 4 weeks; max 60 mg/day.
Terminal elimination half-life is approximately 5 hours (range 3-6 hours) in adults; prolonged in hepatic impairment.
14 hours (terminal); extended-release formulation allows once-daily dosing
Hepatic via glucuronidation; primarily metabolized by UGT2B7; minor CYP450 involvement.
Primarily hepatic via CYP3A4; also conjugated by glucuronidation. Metabolites include active beta-hydroxy acid.
Primarily hepatic metabolism (CYP3A4 and glucuronidation); <5% excreted unchanged in urine; ~70% excreted as metabolites in urine, ~30% in feces.
Renal (10% as active metabolites, 83% as inactive metabolites in urine); fecal (5%)
Approximately 50% bound to plasma proteins, primarily albumin.
91-95% bound to plasma proteins (primarily albumin)
Approximately 2.6 L/kg (range 1.6-3.8 L/kg); indicates extensive tissue distribution.
0.96 L/kg; indicates distribution into extravascular tissues
Intramuscular and subcutaneous: approximately 80%; oral: low (extensive first-pass metabolism, <20% oral bioavailability).
14-26% for extended-release tablets; food increases rate but not extent of absorption
Cr Cl 30-50 m L/min: administer 75% of normal dose; Cr Cl 10-29 m L/min: administer 50% of normal dose; Cr Cl <10 m L/min: avoid use or use with extreme caution.
e GFR 30-80 m L/min: No adjustment. e GFR <30 m L/min: Use with caution, max dose 20 mg/day.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25%; Child-Pugh Class C: reduce dose by 50% or avoid.
Contraindicated in active liver disease or unexplained persistent transaminase elevations. Child-Pugh Class A: No dose adjustment. Child-Pugh Class B or C: Not recommended (no data).
0.1-0.2 mg/kg IV/IM/SC every 3-6 hours as needed; maximum single dose 20 mg.
Not approved for patients <20 years (safety and efficacy not established).
Initiate at 50% of adult dose (5-10 mg) and titrate cautiously due to increased sensitivity and risk of respiratory depression.
Start at low end of dosing range (20 mg/day) due to increased risk of myopathy; monitor renal function and muscle symptoms.
Risk of respiratory depression, abuse, misuse, and addiction; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
None.
Respiratory depression; abuse potential; neonatal opioid withdrawal syndrome; adrenal insufficiency; severe hypotension; head injury and increased intracranial pressure; severe hepatic or renal impairment.
Myopathy/rhabdomyolysis risk, especially with concurrent use of CYP3A4 inhibitors (azole antifungals, macrolide antibiotics, protease inhibitors, grapefruit juice),Hepatic enzyme elevations (monitor transaminases before and during therapy),Use with caution in patients with renal impairment,Avoid in pregnancy and lactation
Hypersensitivity to nalbuphine or any component; significant respiratory depression; acute or severe bronchial asthma; paralytic ileus; suspected or known gastrointestinal obstruction; use of MAOIs within 14 days.
Active liver disease or unexplained persistent transaminase elevations,Hypersensitivity to lovastatin or any component,Pregnancy,Lactation,Concurrent use of strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, boceprevir, telaprevir, nefazodone, cobicistat)
No specific food interactions. Avoid grapefruit juice as it may theoretically increase nalbuphine levels (CYP3A4 substrate, though major metabolism via glucuronidation). Maintain adequate hydration to prevent constipation.
Grapefruit juice increases lovastatin blood levels and risk of toxicity. Avoid grapefruit products. High-fat meals may increase absorption; take with evening meal for optimal effect.
Pregnancy Category C. No adequate well-controlled studies in pregnant women. Animal studies have shown no teratogenic effects but embryocidal effects at high doses. Use only if potential benefit justifies risk. In first trimester, avoid unless necessary. Second and third trimesters: risk of neonatal respiratory depression, withdrawal if chronic use. Near term: may prolong labor and cause neonatal respiratory depression.
FDA Pregnancy Category X. Contraindicated in pregnancy due to risk of fetal harm (HMG-Co A reductase inhibition may interfere with cholesterol synthesis necessary for fetal development). First trimester: high risk of congenital anomalies, including CNS and skeletal defects. Second and third trimesters: continued risk of fetal toxicity; placental transfer demonstrated in animal studies.
Excreted in breast milk in small amounts; M/P ratio approximately 0.47-1.5. Limited data; caution recommended. Monitor infant for sedation and respiratory depression. Benefits of breastfeeding should outweigh risks.
Contraindicated in breastfeeding. HMG-Co A reductase inhibitors may reduce cholesterol levels in breast milk, potentially adverse effects on infant lipid metabolism. M/P ratio not established for lovastatin; limited data suggest low excretion, but risk outweighs benefit.
No specific dose adjustment recommended for pregnancy, but pharmacokinetics may be altered due to increased volume of distribution and clearance. Dosing should be on an individual basis, titrated to effect. Use lowest effective dose and shortest duration. During labor, doses should be reduced due to potential for respiratory depression in neonate.
No dose adjustment applicable; drug is contraindicated in pregnancy. If exposure occurs, discontinue immediately. Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced clearance) would theoretically reduce efficacy, but no recommendation for dose adjustment due to contraindication.
Nalbuphine is a mixed agonist-antagonist opioid with ceiling effect on respiratory depression; less abuse liability than morphine. Useful for opioid-induced pruritus (e.g., with morphine) at low doses (0.1 mg/kg IV). May precipitate withdrawal in opioid-dependent patients. Avoid in opioid-tolerant patients on full agonists. Metabolized by liver; adjust dose in hepatic impairment. Not a controlled substance (US), but report to regulatory authorities as required.
ALTOPREV (lovastatin extended-release) should be taken with the evening meal to maximize absorption. Avoid grapefruit juice. Monitor liver function and creatine kinase. If used with fibrates, caution for myopathy/rhabdomyolysis. Not recommended in severe renal impairment (Cr Cl <30 m L/min).
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,May cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how nalbuphine affects you.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness, respiratory depression, coma, or death.,Do not stop suddenly after prolonged use; withdrawal symptoms may occur but are generally milder than with full agonists.,Report any signs of allergic reaction (rash, hives, swelling) or difficulty breathing immediately.,If you have been taking other opioids, inform your doctor to avoid withdrawal symptoms.,Store at room temperature away from heat, light, and moisture; keep out of reach of children.
Take exactly as prescribed, once daily with the evening meal.,Avoid grapefruit and grapefruit juice during treatment.,Report unexplained muscle pain, tenderness, or weakness.,Avoid alcohol consumption; inform your doctor if you have liver disease.,Routine blood tests are needed to monitor liver function and cholesterol levels.
"The combination of trifluoperazine, a phenothiazine antipsychotic, with nalbuphine, a mixed opioid agonist-antagonist, can lead to additive central nervous system (CNS) depression, including increased sedation, respiratory depression, and hypotension. Trifluoperazine may enhance the depressant effects of nalbuphine on the brainstem respiratory centers and vasomotor centers. Clinically, this interaction may result in excessive sedation, respiratory compromise, and orthostatic hypotension, particularly in elderly or debilitated patients."
"Combined use of nalbuphine, a mixed opioid agonist-antagonist, with entacapone, a catechol-O-methyltransferase (COMT) inhibitor, may increase the risk of opioid-related adverse effects, including respiratory depression and sedation, due to additive central nervous system depression. Entacapone can also inhibit the metabolism of catecholamines, potentially exacerbating opioid-induced constipation and urinary retention. Clinically, patients may experience enhanced sedation or respiratory compromise, particularly in elderly or debilitated populations."
"Concomitant use of clozapine and nalbuphine may potentiate central nervous system (CNS) depression, leading to additive sedative and respiratory depressant effects. Both drugs act on the CNS via distinct mechanisms but converge on common pathways, increasing the risk of hypotension, bradycardia, and profound sedation. Clinically, patients may experience excessive drowsiness, confusion, or respiratory compromise, particularly in those with pre-existing comorbidities or concurrent use of other CNS depressants."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NALBUPHINE HYDROCHLORIDE vs ALTOPREV, answered by our medical review team.
NALBUPHINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Mixed agonist-antagonist at mu-opioid receptor; full agonist at kappa-opioid receptor; weak antagonist at mu-opioid receptor.. ALTOPREV is a HMG-CoA Reductase Inhibitor (Statin) that works by Competitive inhibitor of HMG-Co A reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to upregulation of LDL receptors and increased clearance of LDL cholesterol.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NALBUPHINE HYDROCHLORIDE and ALTOPREV depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NALBUPHINE HYDROCHLORIDE is: 10-20 mg IM/IV/SC every 3-6 hours as needed; maximum single dose 20 mg, maximum daily dose 160 mg.. The standard adult dose of ALTOPREV is: Lovastatin extended-release: Initial 20, 40, or 60 mg orally once daily at bedtime; titrate every 4 weeks; max 60 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NALBUPHINE HYDROCHLORIDE and ALTOPREV in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NALBUPHINE HYDROCHLORIDE is classified as Category A/B. Pregnancy Category C. No adequate well-controlled studies in pregnant women. Animal studies have shown no teratogenic effects but embryocidal effects at high doses. Use only if pot. ALTOPREV is classified as Category C. FDA Pregnancy Category X. Contraindicated in pregnancy due to risk of fetal harm (HMG-CoA reductase inhibition may interfere with cholesterol synthesis necessary for fetal developm. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.